TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06296212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAD® 600 mg/4 mL powder and solvent for solution for injection
Description: TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution 0.9% of sodium chloride
Description: Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
Study: NCT06261268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strip graft with Mucograft
Description: An apically repositioned flap is made in the vestibular region. The flap is then elevated with a split-thickness preparation, and the mucogingival junction will be repositioned apically and fixed with periosteal-anchored sutures. Then, a free epithelialized gingival strip graft will be harvested from the molar area of the palate. The Strip graft is sutured to the apical end of the recipient bed. The remaining uncovered part of the periosteal bed will be covered with a xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) fixed with simple interrupted and crossed sutures. The edges of the palatal wound (donor area) will be approximated with crossed sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: The preparation of the apically repositioned flap and the recipient bed with its apico-coronal design and dimension is performed as in the test group. Subsequently, an epithelialized free gingival graft with the size of the entire recipient area with a thickness of 2 mm will be harvested from the molar area of the palate. The graft is sutured to the recipient periosteal bed using simple interrupted and crossed sutures. In the donor area, a collagen sponge is sutured to the wound by means of crossed sutures.
Study: NCT04637113

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study.
Study: NCT05937373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose monitor
Description: Perioperative glucose management beginning preoperative through postoperative monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: no study intervention. participant follows current medical providers recommendations for glucose management
Study: NCT04996797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: Administered by IV infusion

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Companion Diagnostic (CDx) Testing
Description: PRA023 CDx Genotyping Assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Companion Diagnostic (CDx) Testing
Description: PRA023 CDx Genotyping Assay

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by IV infusion
Study: NCT05330455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3965193
Description: GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3965193
Description: GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3965193
Description: GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3965193
Description: GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3965193
Description: GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3965193
Description: GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3965193
Description: GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3965193
Description: GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK3965193
Description: Placebo to match GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK3965193
Description: Placebo to match GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK3965193
Description: Placebo to match GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK3965193
Description: Placebo to match GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK3965193
Description: Placebo to match GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK3965193
Description: Placebo to match GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK3965193
Description: Placebo to match GSK3965193 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered
Study: NCT05768919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 1
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 2
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 3
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Adjuvant Cycles 11-34 Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period 4a
Description: Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: 35+ Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks
Study: NCT05026008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR1375
Description: The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
Study: NCT04844775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L
Description: 1. Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.
Study: NCT05139056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neural Stem Cells-expressing CRAd-S-pk7
Description: Given intracerebrally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT04620239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: padeliporfin VTP
Description: During treatment, placement at the target area of an optical light fiber, through the working channel of the ureteroscope. Intravenous administration of padeliporfin at the dose of 3.66 mg/kg infused over 10 minutes. Each target area will be illuminated for 10 minutes.
Study: NCT06357364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and cognitive modules
Description: Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and cognitive modules
Description: Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral module: Starting on Time and Planning Realistically
Description: Learning of realistic planning, and timely starting of work.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral module: Working Time Restriction
Description: Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
Study: NCT05638659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized dual-task balance and home program
Description: Portable force plate with aluminum top plate for measuring ground reaction forces, moments and the center of pressure in biomechanics. Through software to collect data from the force plates, converts the trials into useful information and plots the results. The force plates and charge amplifiers are fully remote controlled by software thus making the system extremely flexible and easy to use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical consultation and traditional balance training
Description: Participants were assigned to read the health education flier and were assessed directly.
Study: NCT04774926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: 120 mg/ml solution for intravitreal injection
Study: NCT06101069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRF in conjunction with IVIM MRI without contrast
Description: MRF in conjunction with IVIM MRI scan, without contrast.
Study: NCT04844775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)
Description: 1. Drep-HIV-PT1 1mg (see above)~2. Drep-HIV-PT1 1mg (see above)
Study: NCT06269861

Intervention type: DEVICE
Group type: OTHER
Intervention: patient transfer scale
Description: patient transfer scale is a device to measure actual weight for critically ill patient who are unable to stand

Intervention type: DEVICE
Group type: OTHER
Intervention: patient transfer scale
Description: patient transfer scale is a device to measure actual weight for critically ill patient who are unable to stand
Study: NCT04792580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: Used twice a day in both eyes for 4 weeks after a 2 week washout.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
Study: NCT05640921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gi-CBT
Description: Gi-CBT designed to cover relevant aspects of tackling trauma, and the CBT component will involve addressing negative thoughts, building more positive ones and building resilience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Orientation
Description: The MO sessions will embed media content to create awareness of the government's approaches to reintegration.
Study: NCT05107739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug Product De-TIL-0255
Description: Autologous tumor-infiltrating lymphocytes
Study: NCT06480422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental breathing technique
Description: To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly. Blow patient's nose and huff, cough to clear your upper airways to mucus. This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath. Hold the breath for three seconds. With some gentle force exhale all the air out of your lungs. Repeat three times. Do not cough untill after the third breath. Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, 20 and 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autogenic drainage
Description: To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly.Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, which should take between 20 and 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autogenic drainage
Description: To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly.Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, which should take between 20 and 45 minutes.
Study: NCT04844775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 4mg and CN54gp140/MPLA-L
Description: 1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~2. CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.
Study: NCT05107739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug Product De-TIL-0255
Description: Autologous tumor-infiltrating lymphocytes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug Product De-TIL-0255
Description: Autologous tumor-infiltrating lymphocytes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug Product De-TIL-0255
Description: Autologous tumor-infiltrating lymphocytes
Study: NCT05207605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Stabilization (RS)
Description: Group A includes rhythmic stabilization technique. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively. The total duration of RS will be of approximately 33 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie technique
Description: McKenzie technique will be guided to conduct four extension exercises and three flexion exercisesAll flexion exercises will be repeated for ten repetitions for two sets. There are three minutes for resting intervals in every set. The McKenzie treatment will lasted for 20-40 minutes.
Study: NCT04830514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommended Dietary Allowance of Protein
Description: 0.8 g/kg/day protein intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual protein intake
Description: 1.0 g/kg/day protein intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Protein Intake
Description: 1.5 g/kg/day protein intake
Study: NCT06647498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug
Description: Administered subcutaneously every 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remternetug
Description: Administered subcutaneously every 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Remternetug)
Description: Administered as subcutaneous injection of placebo every 12 weeks
Study: NCT05394714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magicell-NK contains NK cells suspended in 100 mL normal saline
Description: Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
Study: NCT04589325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months.
Study: NCT06064604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The stroke survivors will serve as their own control group. The participants will complete the required tasks without an exoskeleton device.
Study: NCT05148533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ1133 Injection
Description: TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
Study: NCT06064604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip Exoskeleton
Description: The Georgia Tech Hip Exo is a wearable robotic device for hip extension/flexion assistance. This device will be used to study the lower limb movement and how to effectively assist users. It makes use of a responsive controller that considers information such as joint angles to understand the user's state and assists with the appropriate level of power accordingly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Exoskeleton
Description: The Dephy Exoboot is a lower limb exoskeleton which attaches to the user below the knee through a cuff at the proximal calf and a provided shoe. This investigational device is used to make it easier for able-bodied and impaired individuals to walk and run under a variety of conditions. The exoskeleton provides assistance at the ankle joint during movement. The purpose is to assist the user in lower limb movements such as ground level walking, climbing stairs/ramps, and sit-to-stand.
Study: NCT05483270

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: the timing of embryo transfer in freeze-all cycles
Description: Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the timing of embryo transfer in freeze-all cycles
Description: Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval.
Study: NCT05243641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib will be supplied at 200 mg and 150 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib will be supplied at 200 mg and 150 mg tablets
Study: NCT04824859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team